key: cord-0843177-8h00dx22
authors: Ramirez-Sandoval, Juan C.; Castillos-Ávalos, Valeria Jocelyne; Paz-Cortés, Armando; Santillan-Ceron, Airy; Hernandez-Jimenez, Sergio; Mehta, Roopa; Ricardo, Correa-Rotter
title: ORIGINAL ARTICLEVery Low Vitamin D Levels are a Strong Independent Predictor of Mortality in Hospitalized Patients with Severe COVID-19
date: 2021-10-15
journal: Arch Med Res
DOI: 10.1016/j.arcmed.2021.09.006
sha: be2f974ee5d48ff484cf209f1c0c7768e7ac0ce8
doc_id: 843177
cord_uid: 8h00dx22

BACKGROUND: . There is controversy regarding the association between hypovitaminosis D and COVID-19 outcomes. AIM OF THE STUDY: . We assessed the association between 25-hydroxyvitamin D levels and COVID-19 outcomes in hospitalized subjects with severe SARS-CoV-2 infection. METHODS: . Retrospective cohort study. Serum 25-hydroxyvitamin D levels of subjects with severe COVID-19 pneumonia were measured at hospital admission, between March 17(th), 2020, and March 1(st), 2021. RESULTS: . Out of 2,908 patients, 571 (19.6%) had vitamin D deficiency (defined as a serum 25-hydroxyvitamin D level <12.5 ng/mL [<31.25 nmol/L]), and 1069 (36.7%) had levels between 12.5 ng/mL (31.25 nmol/L) and 20 ng/mL 850 nmol/L). Compared to subjects without vitamin D deficiency, those with 25-hydroxyvitamin D level <12.5 ng/mL had higher rates of in-hospital mortality at 30 d (28.0 vs. 17.3%; p <0.001), global mortality (31.9 vs. 20.8%; p <0.001), mechanical ventilation requirement (23.8 vs. 17.2%; p <0.001), and significantly longer hospital stay (median [interquartile range] of 9 [6–17 d] vs. 7 [5–12 d], p <0.001). In the unadjusted analysis, the risk of in-hospital death was greater for patients with vitamin D deficiency (HR 1.43; 95% CI, 1.20–1.70; p <0.001). After adjusting for confounders, the risk of in-hospital death within 30 d remained significantly greater in patients with vitamin D deficiency (HR 1.46; 95% CI, 1.21–1.76; p <0.001). The risk was reduced but remained significant with 25-hydroxyvitamin D levels between 12.5 ng/mL and 20 ng/mL (HR 1.31; 95% CI 1.10–1.55, p = 0.02). In comparison with other clinical biomarkers, vitamin D deficiency was an independent predictive marker of in-hospital mortality after adjusting for confounders. CONCLUSION: . Very low 25-hydroxyvitamin D levels measured at hospital admission were significantly associated with in-hospital mortality and are a useful prognostic biomarker in severe COVID-19 patients.

Low levels of 25-hydroxyvitamin D (vitamin D) have been suggested to be a risk factor for COVID- 19 infection and the severity of the disease caused by SARS-CoV-2 virus (1) (2) (3) . Vitamin D deficiency is a potential modifiable risk factor for worse outcomes in patients with acute respiratory infections, including viral infections (4) . Vitamin D has crucial regulatory roles in the immune response to viral infections established by its anti-inflammatory, antioxidant, and antiviral effects (5) , and thus could be employed as an adjuvant treatment to improve COVID-19 outcomes.

Nevertheless, there is controversy regarding the association between hypovitaminosis D and risk of COVID-19 infection and mortality; particularly, since a large part of the evidence is derived from observational cohort studies with mixed results (2, 6) and underpowered clinical trials (7, 8) . Many health professionals have not only recommended to avoid supplementation of vitamin D, but also are against measuring 25-hydroxyvitamin D at hospital admission of COVID-19 patients (9, 10) .

Recent observational studies have concluded that hypovitaminosis D is not associated with adverse outcomes in hospitalized COVID-19 patients (11, 12) ; however, most of these studies lack sufficient statistical power since the sample size was relatively small (6, (12) (13) (14) or were carried out in subjects with a low mortality risk (15) . Few other observational studies have assessed 25-hydroxyvitamin D many weeks or years before hospitalization and not on the admission day (12, 15) . In a few studies the principal outcome was observed in surrogate endpoints such as D-dimer levels, or C-reactive protein (CRP), yet the association between hypovitaminosis D and clinically important outcomes such as mortality or requirement of respiratory support is commonly inconclusive (2, 16, 17) .

To our knowledge, there are no published cohort studies with a sufficient sample size to allow adjustment of different confounding variables, including exposure to treatments. In this sense, we report the association between 25-hydroxyvitamin D levels and COVID-19 outcome in a large cohort of 2,908 hospitalized, severe patients attending a COVID-19 reference center in Mexico.

This study included COVID-19 patients who required supplemental oxygen, consecutively hospitalized at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (March 17 th , 2020-March 1 st , 2021), a third-level healthcare center in Mexico City designated to treat COVID-19 patients. COVID-19 was confirmed in all patients by RT-qPCR test from nasopharyngeal swabs and/or computerized tomography. All patients had severe COVID-19 as defined by the National Institute of Health criteria of a SpO 2 of less than 94%, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen of (PaO 2 /FiO 2 ) <300 mmHg, respiratory frequency of >30 breaths/min, or lung infiltrates >50% (18) . Patients underwent a chest computerized tomography (CT), and a radiologist determined the degree of pulmonary parenchymal disease. We excluded patients who remained hospitalized after April 1 st , 2021, because the follow-up period of 90 d was incomplete now of the analysis. For readmitted patients the analysis only included the data of the first hospitalization to avoid duplication of patients. Other subjects excluded were those who requested voluntary discharge or were transferred to another institution where full clinical data was not available.

Blood samples were obtained at the time of initial evaluation. Serum 25-hydroxyvitamin D levels were measured at hospital admission in all subjects by chemiluminescence assay using the Abbott Architect I2000 equipment (Santa Clara, USA). Deficiency of vitamin D was defined as a very low level of <12.5 ng/mL (<31.25 nmol/L, to convert to nmol/L, multiply by 2.496). The 12.5 ng/mL cutoff baseline was selected according to the National Health and Nutrition Examination Survey (NHANES) criteria (19) , and considering is the threshold concentration upon which participants in clinical trials have experienced the most consistent benefits of vitamin D supplementation (20) . We also performed an exploratory analysis to investigate COVID-19 outcomes in subgroups defined by a 20 ng/mL and 30 ng/mL cut-off level of vitamin D at hospital admission, since many experts consider that less than 30 ng/mL may also be independently associated with an increased risk of adverse outcomes (21) . Endpoints (in-hospital mortality, global mortality, and requirement of mechanical ventilation) and differences in LOS were compared between subjects with and without vitamin D deficiency using Pearson's  2 test and the U Mann-Whitney test respectively. Kaplan-Meier analysis was conducted to compare survival rates using log-rank test. Univariate and multivariate Cox regression analyses were constructed to assess the unadjusted and multivariate-adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs). In model 1, age (per 10 year increment), sex, obesity (≥35 kg/m 2 ), diabetes, community acute kidney injury, medical treatments (including dexamethasone), hypertension, and presence of one or more comorbidities (cardiovascular or cerebrovascular disease, lung diseases, cancer, chronic kidney disease, solid organ or hematopoietic stem cell transplantation, smoking) were used as covariates for adjustment. Model 2 was adjusted for covariates in model 1 plus other laboratory measurements performed at hospital admission (CRP, D-dimer, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), high-sensitive cardiac troponin I (Hs-cTnI), serum creatinine, PaO 2 at room air, PaO 2 /FiO 2 ratio, and others). Analyses were carried out using In comparison with patients without vitamin D deficiency, patients with vitamin D deficiency were older, had a higher proportion of previous diagnosis of hypertension, diabetes, and chronic kidney disease, their duration from symptom onset to hospital admission was lower, and the proportion of males and previously healthy subjects were lower (Table 1) . Laboratory abnormalities were more common in subjects with vitamin D deficiency such as higher concentrations of D-dimer, LDH, CPK, or Hs-cTnI, as well as lower levels of calcium, hemoglobin, and total lymphocyte count. Table 1 , other parameters showed significant differences between the groups due to the large sample Previous reports in similar populations, including one in our center (23) , have shown a higher mortality risk associated to vitamin D deficiency (16, 17, 24) . Nevertheless, recent publications did not find an association between vitamin D levels and mortality or other important outcomes. For example, Al-Jarallah M, et al. found that overall mortality was not significantly associated to vitamin D levels in 231 hospitalized subjects with severe COVID-19 (13) , and Bianconi V, et al. reported that vitamin D levels were not prospectively associated to the composite endpoint of intensive care unit admission/in-hospital death in 200 patients (14) . In both studies, we believe that the sample size was relatively small, affecting the adjustment for multiple confounders. In another recent publication, Güven M, et al. found that 25-hydroxyvitamin D levels were not associated to in-hospital mortality after adjustment for confounders in 520 patients. However, vitamin D levels were measured one month before the PCR test for COVID-19 (12) . In a similar way, an analysis conducted using UK biobank data found no association between mortality and vitamin D levels obtained around a decade prior to COVID-19 diagnosis (15) . The knowledge about the time interval between vitamin D levels and COVID-19 diagnosis is critical to understand the discrepancies among clinical studies. Our data strongly supports that very low levels of vitamin D are associated to worse prognosis in patients with severe COVID-19 only if the status of vitamin D is assessed now of hospital admission.

Vitamin D measurement could be a powerful prognostic biomarker in COVID-19 subjects, even in the presence of multiple confounders, including exposure to effective treatments. In our center, dexamethasone treatment was not commonly prescribed until the first days of July 2020, when the preliminary results of The Recovery trial were released (25) . After dexamethasone introduction, mortality was reduced 22% (95% CI 8-34%). Nevertheless, in patients who received dexamethasone, mortality and other adverse outcomes remained significantly associated to 25-hydroxyvitamin D levels <12.5 ng/mL (<31.25 nmol/L). The subjects included in this study had an exacerbated inflammatory response represented by high concentrations of ferritin, CRP, or Dimer-D, but the association strength of these biomarkers with mortality was minor when multiple confounders were adjusted. Only LDH and vitamin D had an independent association with in-hospital mortality compared to other acute phase reactants.

The complex interplay between vitamin D and the immune response to viral infections impedes any conclusion about vitamin D deficiency as a causal factor of mortality in COVID-19. Although very low levels vitamin D could decrease ACE-2 expression, increase vascular permeability, and magnify acute lung injury (26) , reverse causation could be an alternative hypothesis which could explain our results.

It is possible that severe SARS-CoV-2 infection could decrease vitamin D concentrations in early phases. In the traditional dogma, 25-hydroxyvitamin D production was considered stable given the constant expression of hepatic 25-hydroxylases, yet recent studies have challenged this concept (21) .

New evidence suggests that non-traditional factors decrease vitamin D production such as aging, body fat percentage, or ethnicity (27) . We hypothesize that COVID-19 patients with severe inflammation might have an early decrease in serum vitamin D levels due to downregulation of CYP2R1, one of the six cytochromes that catalyzes hydroxylation at C-25 of both forms of vitamin D (vitamin D2 and D3) (28) , similar to the metabolic signals induced by fasting, diabetes, or glucocorticoids (29, 30) .

Other plausible mechanism of this "reverse causation" hypothesis includes a decrease in vitamin D binding protein (DBP) levels, the major transport protein of vitamin D. It has been shown that DBP binds to actin and other protein complexes released by lung inflammation; subsequently, the decrease of DBP induces a decrease in total levels of vitamin D (31).

At the time of writing, there are very limited data of clinical trials. A randomized clinical trial published by Murai IH, et al. (7) found that a single high dose of vitamin D3, compared with a placebo, did not reduce hospital length of stay in 240 hospitalized patients with moderate to severe COVID-19. As the authors point out, the trial had a relatively low number of patients with 25hydroxyvitamin D levels <20 ng/mL (<31.25 nmol/L) (n = 108) and was unable to identify differences in rates of in-hospital mortality. The trial joins other small observational studies with a high risk of bias (11) . We believe that a randomized clinical trial in COVID-19 patients with vitamin D levels <12.5 ng/mL (31.25 nmol/L) would be the best approach to determine whether vitamin D supplementation improves the prognosis of COVID-19 or if hypovitaminosis D is an epiphenomenon due to severe inflammation. Unfortunately, there are no ongoing clinical trials in COVID-19 in which the design includes patients with a cut-off level of <12.5 ng/mL (31.25 nmol/L) (32) .

The present observational study has limitations. In our analysis, we adjusted for many confounders, including age, sex, obesity, diabetes, acute kidney injury, hypertension, baseline vital signs, and inflammatory markers of the severity of COVID-19. Despite this extensive adjustment, it is still possible that some amount of unmeasured confounding variables remains. Another limitation is that a chemiluminescence immunoassay was employed to measure vitamin D levels, which may lead to inconsistent results compared to other techniques, including competitive binding protein, radioimmunoassay, or liquid chromatography mass spectrometry. This could be an important issue, especially when values of vitamin D are between 20 ng/mL (50 nmol/L) and 40 ng/mL (100 nmol/L).

However, in our study we selected a cut-off value of 12.5 ng/mL (a very low level) which is associated with less variation (33) . The trajectory of vitamin D concentrations before hospitalization and during the disease course were not available. This data could be important to test the hypothesis that inflammation may drive an inverse acute phase response in vitamin D levels. Treatment data of many experimental drugs were not included in the analyses, as most patients were included in randomized blinded clinical trials. Finally, the single-center design may limit the generalizability of these findings.

In conclusion, this analysis, which constitutes a large patient cohort, confirms that in hospitalized COVID-19 patients a serum vitamin D concentration lower than 12. 

Vitamin D for COVID-19: a case to answer?

Vitamin D insufficiency as a potential culprit in critical COVID-19 patients

Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease

Vitamin D status and ill health: A systematic review

Translating the role of vitamin D 3 in infectious diseases

Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection

Effect of a Single High Dose of Vitamin D3 on

Hospital Length of Stay in Patients with Moderate to Severe COVID-19: A Randomized Clinical Trial

Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease

Sorting out Whether Vitamin D Deficiency Raises COVID-19 Risk

Vitamin D and COVID-19 disease: don't believe everything you read in the papers! Reply to Dr William B. Grant

Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review

Association of 25-Hydroxyvitamin D Level with COVID-19-Related in-Hospital Mortality: A Retrospective Cohort Study

In-hospital Mortality in SARS-CoV-2 stratified by serum 25-Hydroxy-Vitamin D levels: A Retrospective Study

Prevalence of vitamin D deficiency and its prognostic impact on patients hospitalized with COVID-19

Vitamin D concentrations and COVID-19 infection in UK Biobank

Vitamin D status and outcomes for hospitalised older patients with COVID-19

Vitamin D deficiency and COVID-19: A case-control study at a tertiary care hospital in India

COVID-19) Treatment Guidelines. National Institutes of Health

Vitamin D Deficiency -Is There Really a Pandemic?

Towards a trial-based definition of vitamin D deficiency

Vitamin D Metabolism Revised: Fall of Dogmas

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Serum Vitamin D levels are associated with increased COVID-19 severity and mortality independent of visceral adiposity

The impact of ethnicity on clinical outcomes in COVID-19: A systematic review

Effect of Dexamethasone in Hospitalized Patients with COVID-19 -Preliminary Report. Prepr medRxiv

Angiotensin-converting enzyme 2 in lung diseases

Factors affecting 25-hydroxyvitamin D concentration in response to vitamin D supplementation

Metabolism of vitamin D by human microsomal CYP2R1

Fasting-induced transcription factors repress

Vitamin D bioactivation, a mechanism for Vitamin D deficiency in diabetes

Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D

Circulating complexes of the vitamin D binding protein with G-actin induce lung inflammation by targeting endothelial cells

Vitamin D and coronavirus disease 2019 (COVID-19): rapid evidence review

Determining vitamin D status: A comparison between commercially available assays

PaO 2 at room air, mmHg 68.8, 55.6-88.4% 68

C-reactive protein >15 mg/dL, n (%) 262, 47% 1039

The authors greatly appreciate all the hospital staff for their efforts in treating patients and thank all patients involved in this study.

The authors received no specific funding for this work.

 Figure 3 . Forest plot demonstrating the hazard ratios and 95% confidence interval (CI) for in-hospital mortality during a 30 d period after multivariate logistic regression for clinical data in the cohort.